Results suggest that being a carrier of mutations in MAPT, TARDBP, and TREM2 triggers and accelerates the development of FTD proteinopathies that, eventually, yield a more pronounced effect on the the cognitive, behavioral, and brain tissue impacts associated with FTD. Here, TARDBP is linked to proteostasis deficiencies.